A Phase 2 interventional study of Molecular hydrogen inhalation in Mild Cognitive Impairment (MCI), sponsored by University of Ostrava. Recruiting at 1 site in Czechia. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by University of Ostrava · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Cognitive Dysfunction with a site in Czechia — 10 open to participants now, 14 under way, 2 of them phase 3. Cognitive Dysfunction · Czechia.
Among the 36 studies in Cognitive Dysfunction with a site in Czechia, this one is the 26th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 36th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →10 of the 36 studies in Cognitive Dysfunction with a site in Czechia are open now. Recruiting first, the newest first:
Tomas Bata Hospital, Czech Republic · Sites in Czechia
Ages 65+ · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Czechia, Australia, Austria and 14 more countries
Ages 18+
Masaryk University · Sites in Czechia
Ages 60–80 · Healthy volunteers
Masaryk University · Sites in Czechia
Ages 60–80
Bristol-Myers Squibb · Sites in Czechia, United States, Argentina and 16 more countries
Ages 60–85
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 80 across the 30 interventional studies, 800 across the 6 observational. Of the 17 that completed or were terminated, 4 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
University of Ostrava is the lead sponsor of 10 studies on the registry; 4 are open to participants now.
University of Ostrava has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
2 of the studies in Cognitive Dysfunction with a site in Czechia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07042087St. Anne's University Hospital Brno, Czech RepublicLifestyle for the BRAin Health - Time Restricted Eating and Mindfulness | 2026-12 |
| NCT07757542University of OstravaSafety Assessment of H2 Inhalation in Patients With Mild Cognitive Impairment | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Cognitive Dysfunction with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, one-arm, single-center clinical study tested safety and efficacy of one hour daily dosage of H2 gas in a form of inhalation. Dosage is administered during morning hours every working day according to detailed instructions to study participants.
Primary objective: To verify the safety of hydrogen gas inhalation on a sample of patients with mild cognitive impairment (according to the objective opinion of the physician) and diagnosed mild to moderate form of dementia, as well as to verify cognitive abilities via tests from prof. MUDr. Aleš Bartoš, Ph.D. - ALBA (Amnesia Light and Brief Assessment) and POBAV (Naming of pictures and their equipment).
Secondary objective: To assess the effect on specific health indicators (e.g. inflammation, antioxidant capacity, metabolism) by blood sampling as well as blood pressure/pulse measurement and BMI.
Primary endpoint: Inhalation Safety, Questionnaire - Subjective Assessment (ALBA and POBAV).
Secondary endpoints: Biochemical indicators (e.g. inflammation, antioxidant status), blood analysis and BP/Pulse + BMI.
Study population: 50-80 years old participants with mild cognitive declin in overall good health condition.
Inclusion criteria:
Exclusion criteria:
The primary analysis will concentrate on the frequency and severity of adverse events (AEs/SAEs) and ALBA + POBAV scores to evaluate cognitive changes. Descriptive statistics will summarize adverse events, vital signs, and lab results.
In the secondary analysis, we will assess variations in biochemical markers (inflammation, antioxidant capacity, metabolism) and physiological metrics (blood pressure, pulse, BMI) using paired t-tests or Wilcoxon signed-rank tests, depending on how the data is distributed.
Any missing safety data will be conservatively imputed, and multiple imputation techniques will be utilized for efficacy measurements. While there is no formal interim analysis planned, continuous safety monitoring will be carried out.
Results will be shared through summary statistics, tables, and appropriate graphical representations, offering preliminary insights into the feasibility and potential advantages of molecular hydrogen inhalation therapy.
Justification for Molecular Hydrogen as a Potential Intervention Molecular hydrogen (H₂) has emerged as a promising therapeutic agent due to its selective antioxidant and anti-inflammatory properties. Studies suggest that H₂ inhalation may provide neuroprotection by targeting key pathways implicated in cognitive decline.
Key scientific justifications include:
Despite promising preclinical data, the safety profile of H₂ inhalation in MCD patients remains insufficiently characterized. This study aims to establish safety and tolerability parameters, serving as a foundation for future efficacy trials.
Description of the device H2-Air Blend Inhaler is a medical device designed to generate and deliver molecular hydrogen (H₂) gas for therapeutic inhalation. It is manufactured by H2 Medical Technologies s.r.o. and utilizes SPE/PEM electrolysis technology to ensure high-purity hydrogen production.
The device is intended for use in clinical and research settings, where it can provide controlled hydrogen inhalation therapy to patients. It is equipped with multiple safety features and operational modes, making it suitable for a variety of applications.
The device consists of several key components:
Intended use The H2-Air Blend Inhaler is designed to produce molecular hydrogen gas for controlled inhalation therapy. It aims to serve as a potential neuroprotective treatment, especially for those with mild cognitive impairment (MCI).
This device is meant for clinical research settings, where it can be utilized under medical oversight. Studies are underway to evaluate the safety and tolerability of hydrogen inhalation among patients at risk of neurodegenerative disorders.
This device is not for self-use by untrained individuals and should be operated in accordance with the instructions for use (IFU).
Regulatory status H2-Air Blend Inhaler is a medical device currently undergoing clinical evaluation. Its regulatory classification is under assessment, and the device is being tested to ensure compliance with safety and performance standards.
The device:
Risk and safety considerations H2-Air Blend Inhaler has been designed with multiple safety features, but potential risks must be considered.
Potential risks and adverse effects:
Safety measures and risk mitigation:
Study procedures description Demographics and baseline characteristics The subject's date of birth, gender, race, height, weight will be recorded at baseline visit.
For body weight measurement, subjects must be undressed with the exception of underwear. For height measurement, subjects must be without shoes; subject's height will be measured by site staff by local standard.
Medical history A detailed medical history for each subject will be obtained at baseline visit. All relevant past or present conditions including concomitant medication, as well as prior surgical interventions will be recorded. In addition, subject's history of tobacco, alcohol and caffeine use will be recorded.
MCI - Mild cognitive impairment Mild cognitive impairment (MCI) is a prevalent condition characterized by cognitive decline that exceeds normal aging but does not meet the criteria for dementia.
Vital signs Vital signs include blood pressure and pulse rate.
Physical examination:
This includes examination of the main body systems.
Neurological examination:
The physical examination includes detailed neurological examination so that the eligibility of patients for this study can be evaluated and confirmed.
Patient questionary European Quality of Life 5 Dimensions questionnaire (EQ-5D-5L) This tool represents a standardized measure of health-related quality of life. It comprises the following five dimensions, each describing a different aspect of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. The result is represented by the EQ-5D-5L index, which is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. The higher the EQ-5D-5L index, the better is health-related quality of life.
In addition, the EQ Visual Analog Scale (EQ-5D VAS) provides a quantitative measure of the patient's perception of their overall health status. EQ-5D VAS is numbered from 0 ("the worst health status you can imagine") to 100 ("the best health status you can imagine").33 In this study, EQ-5D-5L version 3.0 will be used - see Appendix.
Concomitant medication All medications that are considered necessary for the subject's welfare may be used at the Investigator's discretion, however dose of any chronic medications, if applicable, must be stable for at least 90 days prior to study entry. Clinical trial reports will follow accurate and comprehensive documentation of concomitant medications to assess drug safety, efficacy, and potential interactions.
H2-Air Blend Inhaler treatment description The H2-Air Blend Inhaler is a medical-grade device crafted for the safe and controlled inhalation of molecular hydrogen (H₂) gas. It utilizes advanced solid polymer electrolyte (SPE)/proton exchange membrane (PEM) electrolysis technology, guaranteeing the generation of high-purity hydrogen gas with a stable and reliable output.
This device is specifically designed for clinical use and supervised home applications, offering a non-invasive method for cognitive support, neuroprotection, and reducing oxidative stress. Its compact, user-centric design, along with integrated safety features, ensures precision, reliability, and ease of use in both research and therapeutic settings.
Key features and functionalities
Sample Size Estimation This study is an exploratory investigation in its early phase, focusing on collecting preliminary data regarding safety and feasibility rather than identifying statistically significant treatment effects. Due to these aims, no formal sample size calculation has been conducted. Instead, we selected a sample size of 30 participants in accordance with standard practices for pilot clinical studies. This number is deemed adequate to detect trends in safety, tolerability, and potential cognitive effects, while also allowing for variability estimation in outcome measures. The findings from this study will yield essential insights necessary for planning larger clinical trials that are more statistically robust. If significant trends emerge, they will guide the design of future studies with improved endpoints and stronger statistical frameworks.
Analysis Population The study will define multiple analysis populations to ensure a structured and meaningful evaluation of the collected data.
Statistical Analysis General Descriptive Analysis Descriptive statistical methods suitable for each variable's nature will present all study variables. Unless noted otherwise, data will be summarized individually for each study visit and for changes noted throughout the treatment period.
Continuous Variables Descriptive statistics for continuous variables will include at least number of non-missing observations, mean, standard deviation, minimum, maximum, median and quartiles per study arm.
Categorical Variables In case of categorical items, at least counts and percentages are presented as well as the number of missing and of non-missing observations per study arm and site.
Demographic and Other Baseline Characteristics Demographic information and baseline traits will be summarized descriptively to give an overview of the study group. Continuous variables like age, weight, height, and initial cognitive scores will be summarized in tables detailing central tendency and variability. Categorical variables, such as sex, race, and medical history, will be displayed in frequency tables.
Primary Analysis The main analysis will examine the occurrence and seriousness of adverse events (AEs) and serious adverse events (SAEs) during the intervention period. Descriptive statistics will be used to analyze the distribution of adverse events, comparing event rates across relevant subgroups. Adverse event severity will be categorized based on the Common Terminology Criteria for Adverse Events (CTCAE), while trends in event frequencies over time will also be assessed. The analysis will encompass an evaluation of treatment-related adverse effects and any unforeseen safety issues.
Secondary Analysis The secondary analysis will examine shifts in cognitive function and quality of life from baseline to post-treatment visits. Cognitive scores, evaluated through the ALBA and POBAV tests ,will be compared using paired t-tests or alternative non-parametric methods, based on the data distribution. Quality of life evaluations, assessed via the EQ-5D-5L, will be analyzed using comparable approaches.
Additionally, exploratory analyses may assess relationships between cognitive changes and other variables, including baseline health characteristics or adherence to the intervention.
Safety Analysis Safety analyses will utilize the safety evaluation set (SES). Descriptive statistics will be presented for all treatment-emergent adverse events (TEAEs), covering both the frequency and severity of reported symptoms. The analysis will distinguish among events related to the investigational device, those with an uncertain relationship, and those assessed as unrelated.
Detailed reporting will cover serious adverse events (SAEs), serious adverse device effects (SADEs), anticipated serious adverse device effects (ASADEs), and unanticipated serious adverse device effects (USADEs). The analysis will also evaluate adverse events that led to study discontinuation or were classified as life-threatening.
For continuous safety parameters like vital signs, changes from baseline will be assessed using summary statistics and visualized when applicable. If noteworthy trends in safety parameters arise, additional sensitivity analyses may be conducted to evaluate potential risk factors.
Efficacy analysis The selection of the statistical test will be based on the scope and characteristics of the data to meet the relevant criteria and provide statistically significant results. Efficacy outcomes will be evaluated by comparing changes in cognitive function and quality of life scores from baseline to post-treatment visits. A paired t-test will be used for the primary comparison if the data distributions satisfy normality assumptions; otherwise, a Wilcoxon signed-rank test will be utilized. For categorical efficacy measures, such as cognitive status classification or subjective patient-reported outcomes, the differences between pre- and post-treatment assessments will be assessed using the chi-square test. If any of the criteria for the mentioned tests, such as data normality or sample size, are not met, an appropriate alternative test will be used, such as the Friedman test, the Kolmogorov-Smirnov test, or another suitable test. As this is a pilot study, formal testing of statistical significance will not be conducted, but probability values will be reported to reflect the strength of the observed effects.
Interim Analysis There are no formal interim analyses planned because of the study's exploratory nature. Nevertheless, ongoing safety monitoring will occur during the study, and if any unexpected trends arise, adjustments to the study protocol may be made.
Handling of Missing Data/ Dropouts
Participants identified as ineligible during screening or who do not meet the inclusion criteria will be replaced to sustain the target sample size. However, those who withdraw from the study after the baseline assessment will not be substituted. In regard to reporting adverse events, any missing values will be filled in using conservative assumptions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1-hour molecular hydrogen inhalation 5 days per week
Combination Product: Molecular hydrogen inhalation
1-hour inhalation of 4% molecular hydrogen
Occurrence of adverse events
Incidence of adverse events including serious adverse events
Time frame: From enrollment to the end of study at 24 weeks
Changes in cognitive functions within 12 weeks
ALBA (Amnesia Light and Brief Assessment) test is used for testing of cognitive functions. The absolute lower limit of the test score is 0 points, and the maximum is 12 points. Normal values is 6-12 points. 0-5 points means cognitive decline.
Time frame: From enrollment to the end of treatment at 12 weeks
Changes in mnestic functions within 12 weeks
POBAV (Naming of pictures and their equipment) test is used for testing of mnestic functions. The absolute lower limit of the test score is 0 points, and the maximum is 20 points. Normal values is 6-20 points. 0-5 points means cognitive decline.
Time frame: From enrollment to the end of treatment at 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — only IPD used in the results publication
Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.
Of 145 non-industry phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 64. This study's planned 14 months is below that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ostrava